Becotatug Vedotin

DRUG16 trials

Sponsors

Kai Hu, West China Hospital, Fudan University, First Affiliated Hospital of Guangxi Medical University, Ming-Yuan Chen

Conditions

Adenoid Cystic CarcinomaAdenoid Cystic Carcinoma of the Head and NeckAdjuvant TherapyAntibody-drug ConjugatesAtypical Teratoid/Rhabdoid TumorsBecotatug VedotinChemotherapyCholangiocarcinoma

Phase 1

Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors

RecruitingNCT07584499

Sun Yat-sen UniversityAtypical Teratoid/Rhabdoid Tumors, Diffuse Intrinsic Pontine Gliomas, Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) +7

Start: 2026-05-30End: 2028-05-30Target: 51Updated: 2026-05-13

Phase 2

Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma

Not yet recruitingNCT07303283

Kai HuAdjuvant Therapy, Locoregionally Advanced Nasopharyngeal Carcinoma, Nasopharyngeal Carcinoma (NPC)

Start: 2026-04-15End: 2033-04-15Target: 218Updated: 2026-03-05

A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Not yet recruitingNCT07381075

West China HospitalHead and Neck Squamous Cell Carcinoma

Start: 2026-02-01End: 2029-06-01Target: 120Updated: 2026-02-02

Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma

Not yet recruitingNCT07394244

Fudan UniversityCutaneous Squamous Cell Carcinoma (CSCC)

Start: 2026-01-09End: 2028-12-31Target: 38Updated: 2026-02-06

Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer

Not yet recruitingNCT07490119

Fudan UniversityRAS Wild Type mCRC

Start: 2026-06-01End: 2029-06-01Target: 31Updated: 2026-03-24

Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy

RecruitingNCT07496190

Sun Yat-sen UniversityNasopharyngeal Cancinoma (NPC)

Start: 2026-02-10End: 2034-02-10Target: 59Updated: 2026-04-13

EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant Treatment of Advanced Penile Cancer

Not yet recruitingNCT07518979

Jiyan LiuPenile Cancer

Start: 2026-05-01End: 2031-05-01Target: 60Updated: 2026-04-09

A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Recurrent Sinonasal Adenoid Cystic Carcinoma

RecruitingNCT07522879

Eye & ENT Hospital of Fudan UniversityAdenoid Cystic Carcinoma, Sinonasal Carcinoma

Start: 2026-05-01End: 2030-07-01Target: 40Updated: 2026-05-12

Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2

Not yet recruitingNCT07531979

Tianjin Medical University Cancer Institute and HospitalBecotatug Vedotin, Chemotherapy, EGFR ADC +3

Start: 2026-04-01End: 2029-12-31Target: 93Updated: 2026-04-15

Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

Not yet recruitingNCT07555860

Sun Yat-sen UniversityNasopharyngeal Carcinoma

Start: 2026-04-20End: 2029-12-31Target: 28Updated: 2026-04-29

ADC and SBRT for Recurrent/Metastatic Salivary Gland Carcinoma

Not yet recruitingNCT07579598

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityAdenoid Cystic Carcinoma of the Head and Neck, Antibody-drug Conjugates, SBRT

Start: 2026-05-01End: 2027-12-12Target: 40Updated: 2026-05-12

Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II Study

Not yet recruitingNCT07589049

Sun Yat-sen UniversityHead and Neck Squamous Cell Carcinoma

Start: 2026-05-01End: 2029-05-01Target: 42Updated: 2026-05-15

Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations

Not yet recruitingNCT07598318

Sir Run Run Shaw HospitalCholangiocarcinoma

Start: 2026-05-20End: 2028-12-31Target: 164Updated: 2026-05-20

Phase 3

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

RecruitingNCT07459296

First Affiliated Hospital of Guangxi Medical UniversityNasopharyngeal Carcinoma (NPC)

Start: 2026-03-05End: 2032-04-01Target: 266Updated: 2026-03-16

Efficacy and Safety of SBRT Combined With Becotatug Vedotin (MRG003) in EGFR-Positive Metastatic Tumor Patients With Oligometastases

RecruitingNCT07481799

Ming-Yuan ChenOligo-metastatic Cancer

Start: 2026-02-06End: 2030-02-28Target: 200Updated: 2026-04-02

Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma

Not yet recruitingNCT07524413

Sun Yat-sen UniversityNasopharyngeal Cancer, Nasopharyngeal Cancinoma (NPC)

Start: 2026-04-01End: 2032-04-01Target: 514Updated: 2026-04-13